


(i) a 15 to 26-residue deleted peptide or deleted peptide analogue comprising formula (I) which forms an amphipathic α -helix in the presence of lipids and in which one or two helical turns of the peptide or peptide analogue are optionally deleted :



or a pharmaceutically acceptable salt thereof, wherein:

- X_1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);
- X_2 is an aliphatic residue;
- X_3 is a Leu (L) or Phe (F);
- X_4 is Glu (E);
- X_5 is an aliphatic residue;
- X_6 is Leu (L) or Phe (F);
- X_7 is Glu (E) or Leu (L);
- X_8 is Asn (N) or Gln (Q);
- X_9 is Leu (L);
- X_{10} is Leu (L), Trp (W) or Gly (G);
- X_{11} is an acidic residue;
- X_{12} is Arg (R);
- X_{13} is Leu (L) or Gly (G);
- X_{14} is Leu (L), Phe (F) or Gly (G);
- X_{15} is Asp (D);
- X_{16} is Ala (A);
- X_{17} is Leu (L);
- X_{18} is Asn (N) or Gln (Q);
- X_{19} is a basic residue;
- X_{20} is a basic residue;
- X_{21} is Leu (L);
- X_{22} is a basic residue;
- X_{23} is absent or a basic residue;
- Z_1 is R_2N- or $RC(O)NR-$;
- Z_2 is $-C(O)NRR$ or $-C(O)OR$;

SUB D)
Cont

each R is independently -H, (C₁-C₆) alkyl, (C₁-C₆) alkenyl, (C₁-C₆) alkynyl, (C₅-C₂₀) aryl, (C₆-C₂₆) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one more bonds between residues 1-7 are

independently a substituted amide, an isostere of an amide or an amide mimetic;

each "-" between residues X₁ to X₂₃ and between residues of the peptide to Z₂ independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic.

56. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which one helical turn is deleted.
57. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which three, four, six, seven or eight residues X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈, X₁₉, X₂₀, X₂₁ and X₂₂ are deleted.
58. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 3 consecutive residues are deleted.
59. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 4 consecutive residues are deleted.
60. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which two non-contiguous sets of 3 consecutive residues are deleted.
61. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which two non-contiguous sets of 4 consecutive residues are deleted.
62. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.

63. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 6, 7 or 8 consecutive residues are deleted.

64. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which residues 19, 20 and 22 are not deleted.

65. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which residues 3, 6, 9 and 10 are not deleted.

66. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which X_{23} is absent.

67. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1 in which:
the "-" between residues designates $-C(O)NH-$;
 Z_1 is H_2N- ; and
 Z_2 is $-C(O)OH$ or a salt thereof.

68. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobic moment, $\langle\mu_H\rangle$, is about 0.45 to about 0.65.

69. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 68, in which the mean hydrophobic moment, $\langle\mu_H\rangle$, is about 0.50 to about 0.60.

70. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity, $\langle H_o \rangle$, is about -0.050 to about -0.070.

71. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity, $\langle H_o \rangle$, is about -0.030 to about -0.055.

72. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, is about 0.90 to about 1.20.
73. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 72, in which the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, is about 0.94 to about 1.10.
- SUB D3
const } 74. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the pho angle is about 160° to about 220° .
75. (Amended) The 15 to 26-residue deleted peptide or peptide analogue of Claim 74, in which the pho angle is about 180° to about 200° .
- SUB D4) 79. (Amended) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a deleted peptide or deleted peptide analogue according to Claim 1 or 57.
82. (Amended) The pharmaceutical composition of Claim 79 which is a lyophilized powder.
- SUB D5 } 83. (Amended) The pharmaceutical composition of Claim 79 which is a solution.